Senores Pharmaceuticals Limited has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for 10 pharmaceutical products across therapeutic segments such as cardiovascular health, central nervous system disorders and pain management. This development is a key advancement in the company’s plan to expand its footprint in Southeast Asia and improve patient access to cost-effective treatments.
With a combined market value of USD 23 million for these products in the Philippines, the approvals present Senores with a sizeable opportunity to serve a growing healthcare demand in the region. Commenting on the achievement, Swapnil Shah, Managing Director, said that the authorizations reinforce the company’s mission to provide high-quality, affordable medicines and further solidify the Philippines as a vital market in its regional growth roadmap.
Backed by these regulatory clearances and robust manufacturing strength, Senores is now positioned to accelerate its presence across the Asia-Pacific region by leveraging its technical expertise, global networks and rigorous quality systems. Senores Pharmaceuticals Limited is a research-oriented global drug manufacturer with a diversified portfolio serving the US, Canada and other regulated and emerging markets.
The company currently has 32 approved ANDAs and 32 CMO/CDMO commercialized products in the United States and supplies generic medicines across more than 40 countries. Its Chhatral manufacturing facility alone carries approvals from regulators in over 10 nations, supported by 390+ product registrations and more than 820 product applications.
Senores also produces critical-care injectables and Active Pharmaceutical Ingredients (APIs). The company operates two formulation plants—one in Atlanta, USA (USFDA approved and DEA/BAA compliant) and another in Chhatral, Ahmedabad (WHO-GMP certified)—along with two API facilities in Gujarat. With three R&D centres across India and the United States, Senores continues to focus on developing technologically differentiated and complex generics for global markets.
